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Abstract

Background: American Diabetes Association (ADA) recommends psychosocial assessment for people with
diabetes, including diabetes-related distress. Elevated diabetes-related distress is associated with poor selfmanagement, lower medication adherence, and poorer quality of life. Insulin delivery methods are multiple
daily injections (MDI) or continuous subcutaneous insulin infusion (CSII). Because people with type 1 diabetes
mellitus (T1DM) require comprehensive insulin therapy to manage blood glucose, we explored the association
of insulin delivery methods and diabetes distress in this group.
Methods: The U.S. Air Force Diabetes Center of Excellence (DCOE), a specialty clinic for adults who are
Military Health System beneficiaries, administers the validated 17-item Diabetes-related Distress Scale (DDS17) as part of standard care. Patient data were analyzed from June 2015 to August 2016 using SPSS version 22.
Patients were free to choose the method of insulin delivery with minimal or no additional cost.
Results: There were 203 patients with T1DM who completed the DDS-17 as part of standard care during the
time period. Patients were categorized as CSII (57.6%) or MDI (42.4%). Women were significantly more likely
to choose MDI over CSII than men (P = 0.003). DDS-17 scores were low in both groups, and there were no
significant differences in DDS-17 by insulin delivery method. Furthermore, no significant differences were
found in hemoglobin A1c (HbA1c) between CSII (7.9% or 63 mmol/mol) and MDI (8.1% or 65 mmol/mol)
users (P = 0.22) and no significant differences in body mass index (BMI) between patients using CSII
(M = 28.33 kg/m2) and MDI (28.49 kg/m2) users (P = 0.15).
Conclusions: Our study demonstrated that if patients are relatively free to choose the insulin delivery method
(minimal or no financial constraints), there were no differences in diabetes distress scores, HbA1c, or BMI
between CSII and MDI. Therefore, people with T1DM may benefit from choosing the method of insulin
delivery that will enable them to achieve individual goals and manage diabetes-related distress.
Keywords: Type 1 diabetes, Diabetes-related distress, Insulin delivery method, Continuous subcutaneous
insulin infusion (CSII), Multiple daily injections (MDI).

recommends psychosocial assessment as an integrated part
of routine care for people with diabetes, which includes
diabetes-related distress.2 Conceptually, diabetes-related
distress captures people’s perceptions about their diabetes
self-management, support, emotional burden, and health care
quality.1,3

Introduction

D

iabetes requires a ‘‘complex, demanding, and often
confusing set of self-care directives’’ in which ‘‘patients
may become frustrated, angry, overwhelmed, and/or discouraged.’’1 The American Diabetes Association (ADA)
1
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Diabetes-related distress can be assessed using the validated 17-item Diabetes-related Distress Scale (DDS-17),
which measures diabetes-related distress in four distinct domains: (1) emotional burden (EB); (2) physician-related
distress (PD); (3) regimen-related distress (RD); and (4) interpersonal distress (ID) (Table 1).1,3 In addition, there are
three categories for DDS-17 scores: <2.0 = little or no distress; 2.0–2.9 = moderate diabetes-related distress; and
‡3 = high diabetes-related distress.1
Elevated diabetes-related distress is associated with poorer
self-management, lower medication adherence, and poorer
quality of life.4,5 Consequently, greater hemoglobin A1c
(HbA1c) values correlate with higher diabetes-related distress,4–6 whereas lower diabetes-related distress is associated
with increased self-efficacy and physician support.7
The relationship between diabetes-related distress and insulin delivery methods has not been well studied. The concept of satisfaction as it relates to insulin delivery modalities,
however, has a more robust foundation in the literature. Pa-

Table 1. The 17-Item Diabetes-Related
Distress Scale
Emotional burden
1. Feeling that diabetes is taking up too much of my
mental and physical energy every day
2. Feeling angry, scared, and/or depressed when I think
about living with diabetes
3. Feeling that diabetes controls my life
4. Feeling that I will end up with serious long-term
complications, no matter what I do
5. Feeling overwhelmed by the demands of living with
diabetes
Physician-related distress
1. Feeling that my doctor doesn’t know enough about
diabetes and diabetes care
2. Feeling that my doctor doesn’t give me clear enough
directions on how to manage my diabetes
3. Feeling that my doctor doesn’t take my concerns
seriously enough
4. Feeling that I don’t have a doctor who I can see
regularly enough about my diabetes
Regimen-related distress
1. Feeling that I am not testing my blood sugars
frequently enough
2. Feeling that I am often failing with my diabetes
3. Not feeling confident in my day-to-day ability to
manage diabetes
4. Feeling that I am not sticking closely enough to a good
meal plan
5. Not feeling motivated to keep up my diabetes selfmanagement
Interpersonal distress
1. Feeling that friends or family are not supportive
enough of self-care efforts (e.g., planning activities that
conflict with my schedule, encouraging me to eat the
‘‘wrong’’ foods)
2. Feeling that friends or family don’t appreciate how
difficult living with diabetes can be
3. Feeling that friends or family don’t give me the
emotional support that I would like
Responses are on a six-point continuum from 1 = Not a problem;
2 = A slight problem; 3 = A moderate problem; 4 = Somewhat
serious problem; 5 = A serious problem; 6 = A very serious problem.
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tient satisfaction has been analyzed through surveys aimed at
measuring treatment-related satisfaction, such as the Diabetes Treatment Satisfaction Questionnaire (DTSQ or
DTSQc) and the Medical Outcome Study 36-Item ShortForm Survey (SF-36). An earlier study among people with
type 1 diabetes mellitus (T1DM) with a history of poor glycemic management who were randomized to either continuous subcutaneous insulin infusion (CSII) or an intensive
MDI (Aspart and NPH) regimen demonstrated a significant improvement in the subscales of ‘‘general health’’ and
‘‘mental health’’ in the CSII group, in addition to an improvement in HbA1c and glucose stability.8 However, there
was no difference in treatment satisfaction by the DTSQ.8
More contemporary studies utilizing newer pump technology
and longer acting basal insulin in the MDI groups, however,
demonstrated higher satisfaction among CSII users compared
with MDI.9,10 In addition to finding an improvement in satisfaction,10 lower rates of hypoglycemia and hyperglycemia
was demonstrated among the CSII users compared with MDI,
which likely affected treatment satisfaction. In a study by
Hussain et al.,9 the group that augmented their CSII with
continuous glucose monitors (CGM) reported highest treatment satisfaction and health perception scores compared with
MDI and CSII alone.
Because people with T1DM require comprehensive insulin
therapy to manage blood glucose levels, we sought to explore
the association of insulin delivery methods and diabetes
distress in this group. Insulin delivery is achieved with a
combination of basal and bolus (mealtime or prandial) dosing, which attempts to mimic normal pancreatic physiologic
insulin release. Delivery methods include MDI through a
syringe or pen injector or through CSII using a pump. Some
evidence suggests that CSII improves treatment adherence,
provides more accurate insulin dosing, and allows people
to have increased flexibility in their lifestyle; however, this
therapy can be expensive, requires a high level of engagement, and can be technically challenging.11 CSII is recommended for people with T1DM who prefer pump therapy
over MDI and have been able to maintain healthy blood
glucose levels.12,13 A systematic review and meta-analysis
found CSII had modest improvements in HbA1c14; however,
there is no consensus regarding which insulin delivery therapy is best for people with T1DM. Furthermore, data are
lacking about the association of diabetes-related distress with
insulin delivery method. Thus, we explored the relationship
of insulin delivery method (MDI vs. CSII) with diabetesrelated distress in patients with T1DM within multidisciplinary diabetes clinic.
Methods

Wilford Hall Ambulatory Surgical Center Institutional
Review Board approval was obtained for this retrospective
data analysis. Data were collected at the U.S. Air Force
Diabetes Center of Excellence (DCOE) through chart reviews of clinical visits from June 2015 to August 2016. The
DCOE is a Military Health System (MHS) diabetes specialty
clinic, focusing on challenging cases of diabetes including
people with T1DM.
Our population consists of all branches of active duty
military members, retirees, and family members (beneficiaries of the MHS because of their relationship with the active
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duty member or retiree). Patients with T1DM were given a
choice of insulin delivery method (MDI or CSII). Data
concerning CGM use were not reliably recorded in the
electronic record and individual use of CGM was not validated; therefore, this was not included in the analysis.
The DCOE began administering the DDS-17 in June 2015
as standard of care (Table 1). Responses for each item were
on a six-point Likert scale from 1 = Not a problem; 2 = A
slight problem; 3 = A moderate problem; 4 = Somewhat serious problem; 5 = A serious problem; 6 = A very serious
problem. DDS-17 domains were calculated as a sum of the
total and divided by the number of items in each domain: EB
(five items); PD (four items); RD (five items); and ID (three
items). It should be noted that total DDS-17 score should be
avoided as it has less relevance than locating the source of
distress; thus, discussion of the four individual domains will
be presented.15
Inclusion criteria were adults (18 years and older) with
T1DM receiving their diabetes care at the DCOE. As part of
the regular clinical visit, all patients completed the DDS-17
with responses recorded by licensed vocational nurses. After
input, the NoteWriter, an Excel-based clinical note writing
platform created for use at the DCOE, calculated scores for
total DDS-17 and each subscale consistent with established
cut points of <2.0, little or no diabetes-related distress; 2.0–
2.9, moderate diabetes-related distress; or ‡3.0 as high
diabetes-related distress.3 For analysis, the most recent DDS17 scores were used. In addition to the DDS-17, data included
demographics (sex, age, ethnicity/race, and military status).
Data were analyzed using SPSS version 22 (IBM, Chicago,
IL). Univariate analyses were conducted to characterize the
sample according to group membership (CSII vs. MDI). Independent t-tests were conducted to assess differences in
DDS-17 scores in the four domains for each group. Chisquare tests were conducted on each DDS-17 domain to determine if there were significant differences in distribution
of level of diabetes-related distress (low, moderate, high)
between groups.

Results

There were 203 people with T1DM who were seen at the
DCOE and who completed the DDS-17 as part of standard
care during the time period. People with T1DM also included
those with diagnoses of pancreoprivic diabetes mellitus
(n = 14) and latent autoimmune disease in adults (n = 43). People
were categorized by method of insulin delivery as CSII (57.6%)
or MDI (42.4%).
Although people can choose from a variety of CSII, most
used a Medtronic pump (81.2%). People on CSII were significantly more likely to be men (53.1%), white (64.2%), and
a family member of an active duty service member (63.0%)
(Table 2). Significantly more women were on MDI (67.3%)
versus CSII (32.7%). People using CSII had a diagnosis of
diabetes for a significantly longer time than those on MDI
(21.88 years; range, 19.0–78.0 years vs. 14.11 years; range,
<1–58.0 years).
The four DDS-17 subscales were subjected to independent
sample t-tests to examine differences between groups (CSII
vs. MDI). Levene’s test was conducted for all models, all
models were significant; therefore, equal variances were not
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assumed. Normality checks were carried out and assumptions
were met.
To determine if method of delivery influenced DDS-17
domain scores for people with T1DM, t-tests were conducted
comparing DDS-17 subscales in people with T1DM and the
method of delivery, CSII (n = 117) versus MDI (n = 86). Chisquare tests did not reveal significant differences in level of
diabetes-related distress in any domain (Fig. 1). In addition,
no significant differences were found in HbA1c (P = 0.22)
between CSII (7.9% or 63 mmol/mol) and MDI (8.1% or
65 mmol/mol) and no significant differences were found in
body mass index (BMI; P = 0.15) between people with T1DM
using CSII (M = 28.33 kg/m2) and MDI (28.49 kg/m2) (Table 2).
Further exploration of the level of distress within each
insulin delivery method by DDS-17 domain (low, moderate,
high) revealed no significant variation in each domain regarding CSII versus MDI (Fig. 2).
Discussion

In this study, we sought to better understand differences in
diabetes distress levels in people with T1DM who used CSII
versus MDI insulin delivery methods. Although one might
consider advanced insulin-delivery technology to provide the
ability to reduce distress in the T1DM population, we did not
find this to be the case. Indeed, there were no differences in
any of DDS-17 domains between these groups (Fig. 1). These
findings suggest that neither method is better at assisting
patients in reaching clinical goals or in decreasing diabetesrelated distress. Rather, the choice of insulin delivery method, with its associated potential for distress, is likely based on
a variety of individual personal factors. On the one hand,
CSII enables greater fine-tuning of insulin delivery with
programmable basal rates and resources to calculate precise
mealtime doses. Accordingly, this method may appeal to
individuals who are technology savvy and enjoy tinkering
with the latest devices. On the other hand, CSII requires a
permanent connection of a device to the body, which may
make individuals feel more encumbered compared with the
MDI method. It would follow that individuals would naturally gravitate toward the method that provides less distress
for them; of course, this assumes that each method is equally
accessible.
We should also note that the vast majority of people in our
study had low levels of distress in each of the DDS-17 domains (Fig. 2). Although each of the DDS-17 domains might
be attributed to the insulin delivery method, RD is likely most
relevant to our question. RD had very similar levels between
the two groups with >60% having low distress. We believe
our findings support the notion that we should continue to
have a variety of insulin delivery options for our population;
people with T1DM may benefit from choosing the method of
delivery to achieve individual goals.
It is not clear why women chose MDI over CSII at a significant rate in our population, whereas men were equally
likely to use either of the insulin delivery methods. The older
average age of our participants suggests that considerations
regarding pregnancy and influence on preferred treatment
modality were less likely, and recent reviews have suggested
that glycemic control and maternal or neonatal outcomes are
comparable in women choosing either delivery method.16
The decision to choose one mode of delivery over another
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Table 2. Sample Characteristics for Patients with Type 1 Diabetes Mellitus
by Method of Insulin Delivery

Women
Men
Mean age
Mean diabetes duration, years
Ethnicity/race
White
African American
Hispanic/Latino
Asian/Pacific Islander
Military status
Active duty
Retirees
Family members
Clinical measures
HbA1c
BMI, kg/m2

Overall (n = 203), n (%)

CSII (n = 117, 57.6%)

MDI (n = 86, 42.4%)

P

107 (52.7)
96 (47.3)
46.46 (19–87)
18.59

35 (32.7)
51 (53.1)
45.12
21.88

72 (67.3)
45 (46.9)
48.28
14.11

0.003
NS
0.16
<0.001

86
17
12
2

48
20
12
6

134
37
24
8

(66.0)
(18.2)
(11.8)
(3.9)

(64.2)
(45.9)
(50.0)
(25.0)

(35.8)
(54.1)
(50.0)
(75.0)

0.008
NS
NS
NS

16 (7.9)
52 (25.6)
135 (66.5)

7 (43.8)
25 (48.1)
85 (63.0)

9 (56.3)
27 (51.9)
50 (37.0)

NS
NS
0.03

8.0%
28.40

7.9%
28.33

8.1%
28.49

0.22
0.15

HbA1c and BMI were collected at the time of the DDS-17.
BMI, body mass index; CSII, continuous subcutaneous insulin infusion; DDS-17, 17-item Diabetes-related Distress Scale; MDI, multiple
daily injections; NS, no significance; T1DM, type 1 diabetes mellitus.

involves provider–patient conversations about the relative
pros and cons of each approach. It may be possible that there
is an unconscious bias regarding the prescribing providers’
perception of women’s interest or comfort in using a technological solution to manage diabetes.17 Implicit bias is increasingly recognized as a driver of health care disparity in
the treatment of various groups, including women. A recent
International Data Corporation report18 found significant
rates of gender bias in perceptions of women as candidates
for the information technology jobs sector, and this suggests
that there are widespread assumptions about women’s interest in technology. Alternatively, CSII impact on body
image may contribute to lower rates of CSII use by women.19
A review of influences on technology use and efficacy in
T1DM found that women reported feeling more selfconscious about wearing their pump compared with men.19

Regardless of the insulin delivery method chosen, the
mean HbA1c for the participants was statistically and clinically indistinct.20 This is consistent with the findings from a
robust multicenter evaluation of the relative effectiveness of
two approaches that found no difference in long-term HbA1c,
and additionally reported no differences in rates of hypoglycemia or psychological measures between treatment modalities.21 In addition, there was no statistically significant
difference in BMI between those who used CSII and MDI, a
finding consistent with those seen in the REPOSE trial.21
Although CSII has been found to improve HbA1c in
people with type 2 diabetes mellitus compared with MDI,11,22
people with T1DM in our study using CSII did not have
significantly different HbA1c (7.9% or 63 mmol/mol) than
those using MDI (8.1% or 65 mmol/mol). Consistent with
Maiorino et al.,10 our study demonstrated no advantages to

FIG. 1. Independent sample t-tests on DDS-17 domains by method of insulin delivery. DDS-17, 17-item Diabetes-related
Distress Scale.
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FIG. 2.

Level of distress by insulin delivery method and domain.

either CSII or MDI. DDS-17 was not statistically different
between groups.
Strengths and limitations

Our study’s main strength is one that is difficult to replicate
outside the MHS. People on intensive insulin therapy within
the MHS can choose between method of insulin delivery and
type of CSII with little or no cost to the patient. When following the referral process, active duty patients and their
dependents are not billed for CSII and supplies, whereas retirees and their dependents have a 20% copay on device and
supplies. Thus, cost is usually not the primary determinant of
method of insulin delivery. Even in nonmilitary environments, CSII was found to be cost-effective for people with
T1DM who have poor glycemic management as CSII was
associated with improved HbA1c and less hypoglycemia
compared with MDI.23
Despite this strength, several limitations to our study exist.
We did not analyze change in DDS-17 based on change of
therapy (from MDI to CSII and/or CSII back to MDI) or
change over time. The DDS-17 score is also not correlated
with duration of currently chosen delivery method. Our
population, while drawing from a wide array of backgrounds
because of the transient nature of the military, was from one
clinic, predominantly white, relatively well-managed HbA1c,
and low diabetes-related distress across all domains. These data
also may not be as applicable to current trends given the study
was performed before the hybrid closed-loop technology being
made available to our population.
Future research should include evaluation of DDS-17 before and after insulin delivery method changes, both MDI to
CSII and CSII to MDI, along with monitoring of DDS-17
changes in each group over time. The duration a person has
had diabetes or has used a specific insulin delivery method
may also cause differences in DDS-17 scores, and correlation
of DDS-17 with time of MDI and CSII therapy could provide
beneficial information. Comparison between types of insulin

pumps could provide insight into which CSII technology
would provide best outcomes regarding DDS-17. Furthermore, evaluation of CSII users with CGMs versus those
without CGMs could provide understanding to this specific
technology and its association with DDS-17. Other investigations could potentially assess DDS-17 in people on MDI or
CSII outside the MHS, where ease of obtaining your choice
of delivery method is not as readily obtainable because of
other substantiating factors, that is, out-of-pocket expenses.
Our study demonstrated that there were no differences in
diabetes distress scores, HbA1c, or BMI between CSII and
MDI when financial constraints were reduced or removed. As
health care moves toward patient-centered care, people with
T1DM may benefit from choosing the method of delivery that
will enable them to achieve individual goals without increased diabetes-related distress, which may not always increase expense and/or be related to technology.
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